Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

CRISPR has immense therapy upside, but research is outside the USA due to regulation

Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)

CRISPR/Cas9 is a major technological feat with tremendous potential to impact the agriculture and health industries. These tools are currently being used to expedite crop and livestock breeding, engineer new antimicrobials, and control populations of disease-carrying insects (Gao 2018; Nunez and Lu 2017; Hammond et al. 2016). For human health, CRISPR can be used to treat diseases for which gene editing has previously been considered a therapeutic strategy, including Parkinson’s disease, Alzheimer’s disease, muscular dystrophy, cystic fibrosis, sickle cell disease, hemophilia, autism, HIV, and various cancers among other applications (NASEM 2017). Two first-in-human safety trials have been initiated to study whether CRISPR edited immune cells are more efficient at killing tumour cells in people with terminal cancer (Cyranoski 2016; Reardon 2016). CRISPR technology has reportedly been used to correct gene defects in human embryos (Ma et al. 2017) and is considered important in improving assisted reproductive technologies (Simón 2013; Ishii 2017). Research involving human embryo manipulation, however, is largely being conducted outside the United States due to regulatory restrictions. Several of these applications have relevance to Department of Defense (DoD) initiatives.

Sign in to recut, update, or save this card.